George I Papakostas, Madhukar H Trivedi, Richard C Shelton, Dan V Iosifescu, Michael E Thase, Manish K Jha, Sanjay J Mathew, Charles DeBattista, Mehmet E Dokucu, Olga Brawman-Mintzer, Glenn W Currier, William Vaughn McCall, Mandana Modirrousta, Matthew Macaluso, Alexander Bystritsky, Fidel Vila Rodriguez, Erik B Nelson, Albert S Yeung, Anna Feeney, Leslie C MacGregor, Thomas Carmody, Maurizio Fava
Further research is needed to help improve both the standard of care and the outcome for patients with treatment-resistant depression. A particularly critical evidence gap exists with respect to whether pharmacological or non-pharmacological augmentation is superior to antidepressant switch, or vice-versa. The objective of this study was to compare the effectiveness of augmentation with aripiprazole or repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine XR (or duloxetine for those not eligible to receive venlafaxine) for treatment-resistant depression...
March 7, 2024: Molecular Psychiatry